Monocyte-derived dendritic cell (moDC)

Monocyte-derived dendritic cells (moDCs) are a specialized population of antigen-presenting cells that differentiate from circulating monocytes, primarily in response to inflammatory stimuli or specific in vitro cytokine signals such as GM-CSF and IL-4. They play a pivotal role in the immune system by capturing and processing antigens, which they then present via MHC molecules to T cells, effectively bridging innate and adaptive immunity. In therapeutic contexts, moDCs are frequently generated ex vivo to create personalized cancer vaccines, where they are loaded with tumor antigens and matured before being re-infused into patients to elicit a targeted anti-tumor T-cell response. Beyond oncology, moDCs are involved in the pathogenesis of chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, where they may propagate pathogenic T-cell responses. While they are highly effective at antigen cross-presentation and cytokine secretion (e.g., IL-12), their clinical efficacy as vaccines has been variable due to challenges in migration to lymph nodes and suppression within the tumor microenvironment.

Other names

MDDCMo-DCMonocyte-derived DCInflammatory dendritic cellIn vitro-derived dendritic celliDC (immature)mDC (mature)

Monocyte-derived dendritic cells are typically generated ex vivo from CD14+ monocytes using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Interleukin-4 (IL-4) to induce differentiation into immature DCs, which are subsequently matured using Toll-like receptor (TLR) agonists or inflammatory cytokine cocktails to enable robust antigen presentation and T-cell priming.